Biotechnology Industry News
This newspage features a selected set of feeds from biotechnology industry information sources.
- Drug Patent Expirations for Aug 31 2010
If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations ADVERTISE HERE This newsletter is a free service of DrugPatentWatchDrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents Drug Patent Expirations for August 31 2010TradenameApplicantGeneric NamePatent Number Patent ExpirationCOVERA-HSGd Searle Llcverapamil hydrochloride5,232,705Aug 31, 2010*Drugs may be covered by mu... - Drug Patent Expirations for Aug 24 2010
If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations ADVERTISE HERE This newsletter is a free service of DrugPatentWatchDrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents Drug Patent Expirations for August 24 2010TradenameApplicantGeneric NamePatent Number Patent ExpirationCAPOTENPar Pharmcaptopril5,238,924Aug 24, 2010*Drugs may be covered by multiple patents or re... - Drug Patent Expirations for Aug 22 2010
If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations ADVERTISE HERE This newsletter is a free service of DrugPatentWatchDrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents Drug Patent Expirations for August 22 2010TradenameApplicantGeneric NamePatent Number Patent ExpirationZANTAC 150Glaxosmithklineranitidine hydrochloride5,028,432*PEDAug 22, 2010ZANTAC 300Glaxosmit... - Drug Patent Expirations for Aug 21 2010
If your reader cannot render the information below, go to http://www.DrugPatentWatch.com/innovation to see the latest expirations ADVERTISE HERE This newsletter is a free service of DrugPatentWatchDrugPatentWatch offers comprehensive details on FDA approved drugs, developers, and their patents Drug Patent Expirations for August 21 2010TradenameApplicantGeneric NamePatent Number Patent ExpirationCOMMITGlaxosmithkline Consnicotine polacrilex5,110,605Aug 21, 2010NICORETTEGlaxosmithkline Co...
- Experts urge Ghanaians to use and apply modern biotechnology2 September 2010, 2:50 am
Accra, Aug. 26, GNA - Ghanaians have been urged to embrace the use and application of modern biotechnology to effectively solve food insecurity and the likely impact of climate change on farming. Professor Walter Sandow Alhassan, Project Coordinator for...
- New Rules for Biotech Sugar Beets Promised This Year2 September 2010, 1:43 am
statement. They also further U.S.D.A.s continuing efforts to enable coexistence among conventional, organic and biotechnology production systems, Mr. Vilsack said. Roundup Ready seeds were planted on about 95 percent of all sugar-beet acreage earlier... - Biotech will change farm research, says Mayee2 September 2010, 1:35 am
NAGPUR: Biotechnology is fast changing the scope of research in agriculture. It is an ever growing field. It will bring the second green revolution in the country. This was stated by , chairman... - Biotechnology (12)2 September 2010, 12:15 am
Aug. 13, 2009 | http://deltafarmpress.com/epa-bias-against-ethanol...
- Eli Lilly Earns Major Win As Appeals Court Upholds Evista Ban (LLY, TEVA)1 September 2010, 4:43 pm
... - Inhibitex Completes Trial For Hep C Drug1 September 2010, 4:16 pm
... - Intendis Enters Deal With Kythera For Fat-Reduction Drug1 September 2010, 3:53 pm
... - Pluristem Placental Cells Found Effective For Several Treatments30 August 2010, 3:37 pm
...
- Pfizer's Internal Documents Come Back to Haunt after $2.3 Billion Settlement30 August 2010, 4:44 pm
Blue Cross Blue Shield filed a lawsuit earlier this year against Pfizer in an effort to recover reimbursements for illegally promoted drugs such as Bextra. The lawsuit names individual Pfizer employees - all in management roles - and relies in large part of the internal Pfizer memos, reports, emails, presentations, promotional materials, and other records used to force the 2009 settlement with the US Department of Justice for $2.3 billion. One of the points I make with my FDA records management ... - August FDA Newsletter25 August 2010, 3:25 pm
Issue #44 of SmarterCompliance is now available. Content includes: Preparing for an inspection by regulatory health agencies (part four) Cost-effective GCP auditing of CROs Recent FDA 483 citations on supplier qualification Trend watch Leadership quick-tips: Leading with subtlety Book of the month: How to Measure Anything Subscribers have access to six newly published documents including: WHO revised guidance on pharmaceutical GMP distribution & traceability practices MHRA enforcement strategy p... - The 2nd Supplier Quality Management Congress11 August 2010, 1:46 pm
Next Wednesday the opening session of the 2nd Annual Supplier Quality Management Congress will take place in Bethesda, Maryland. The conference will bring together FDA officials, industry experts, quality and regulatory affairs professionals, and of course, people responsible for supplier selection and management. It is a conference that combines the "best of" aspects of pharmaceutical and medical device supplier qualification and oversight so participants get a broad range of best practices to ... - Do's and Don'ts of FDA Supplier Oversight2 August 2010, 6:24 pm
I'll be presenting a teleconference and taking your questions on Thursday, August 12th through FOI Services. The title of my talk: Do's and Don'ts for Selecting, Qualifying and Managing Suppliers in a Global Economy This is very similar to the session I provided for FDA officials recently that was so well received by agency personnel. Here's the high-level agenda: top biopharma and device global business constraints a solutions framework and walkthrough review of SOP components comparison to ISO...
- Infusing Life into the Valley of Death2 September 2010, 6:13 pm
Medical research leaders and patient advocates yesterday participated in a forum that spotlighted the Cures Acceleration Network (CAN) provision of the Patient Protection and Affordable Care Act signed into law by President Obama on March 23, 2010. Speakers and participants were eager to discuss CAN and its potential to transform the medical research enterprise by supporting efforts specifically designed to bridge a gap in the therapeutic development pipeline between basic and clinical research.... - Health Reform Act Creates Cures Acceleration Network to Speed Researchers along the Path to New and Better Treatments for Disease2 September 2010, 6:12 pm
The Patient Protection and Affordable Care Act which President Obama signed into law on March 23rd included a little-discussed, but important provision creating a Cures Acceleration Network (CAN) at the National Institutes of Health (NIH), which will work to reduce the time it takes to move new drugs and therapies from the microscope to the marketplace.This provision, introduced by Senator Arlen Specter (D-PA) as an amendment to the original Senate bill in 2009, creates new funding mechanisms at... - Accelerating Cures by Building a More Effective and Efficient FDA2 September 2010, 6:11 pm
Kristin Schneeman, Program Director, FasterCures A distinguished panel of observers from patient organizations and industry declared themselves to be in “violent agreement” on the urgent need to increase resources and build scientific capacity at the FDA, with one panelist calling it of “strategic importance to the country.” Among the points of agreement were:FDA suffers from an almost scandalous lack of resources. The agency that regulates 25 cents of every dollar U.S. consumers spend h... - Health Reform: Where Do We Go From Here?2 September 2010, 6:10 pm
Cecilia Arradaza, Communications Director, FasterCuresWith the health reform law in place, participants joining this year’s Milken Institute Global Conference had more questions than answers about its implications. A second panel on health reform convened Tuesday (Read Summary of Monday Health Reform Panel) looks at cost, coverage, and consequences.“Cost comes from price [of health care] and utilization,” said Ceci Connolly who covers health policy for The Washington Post. Measures are in ...
- The SuperFreakonomics of IP Licensing: the Licensing Executives Society’s Annual Meeting30 August 2010, 8:42 pm
The Licensing Executives Society is holding its Annual Meeting in Chicago at the Chicago Sheraton Hotel & Towers September 26-29. Themed ‘Deals, Deals and more Deals’ the meeting will focus on the critical role IP plays in today’s most successful business strategies and will explore ways to leverage IP to maximize deal-making and profitability. This [...] Related posts:BIO IPCC Meeting Starts Off With Some Advice From Circuit Judge Michel BIO’s Intellectual Property Counsel Committ... - Patent Buddy’s Top Patent Prosecutors Recognition27 August 2010, 9:37 pm
The Patent Buddy’s blog is looking for nominations for America’s Top Patent Prosecutors. Do you have what it takes? Who is a Top Prosecutor? A Top Patent Prosecutor is any patent attorney who has achieved a reputation among their peers for high quality work product and counseling skills in patent preparation and prosecution. In order [...] Related posts:AwakenIP: Helping to Reignite Recognition of the Value of Intellectual Property Jeff Kuester, a technology attorney with Taylor ... - BioNetwork West 2010: Pharmaceutical-Biotech Partnering Conference20 August 2010, 7:56 pm
BioNetwork West 2010 The 8th Annual Pharmaceutical-Biotech Partnering Conference There are a lot of pharmaceutical and biotechnology investment conferences and Pharma-Biotech networking events in the market. BioNetwork is offering a conference that offers you the chance to spend quality time with the right people. With its intimate setting and extensive networking opportunities, you will meet [...] Related posts:BioOhio Annual Conference Goes On The Road For 2010 BioOhio Annual Conference &#... - Biopolymer Engineering and MIT Fail to Get Vacation (of Summary Judgment)13 August 2010, 3:27 pm
In a nonprecidential opionion, the U.S. Court of Appeals for the Federal Circuit dismissed an appeal by Biopolymer Engineering (Biothera) as moot after it appealed a District Court order granting summary judgment of noninfringement by Immunocorp and Biotec Pharmacon ASA (Biotec). Biopolymer Engineering and MIT v. Immunocorp and Biotec Pharmacon ASA (2010-1096). Biothera sued Biotec [...] Related posts:Supreme Court Certiorari: Summary Dispositions of Classen and Prometheus The Supreme Court ...
- Federal Circuit Grants Injunction Pending Disposition of Lilly v. Actavis Elizabeth2 September 2010, 4:59 am
By Donald Zuhn -- The U.S. Court of Appeals for the Federal Circuit issued an Order today in Eli Lilly & Co. v. Actavis Elizabeth LLC, granting Lilly's request for an injunction to prevent Defendants-Appellees from launching generic versions of Lilly's ADHD drug Strattera® until Lilly's appeal has been resolved. On August 25, Lilly filed a notice of appeal seeking review of a decision by the District Court for the District of New Jersey invalidating Lilly's U.S. Patent No. 5,658,590 for lac... - IPO Comments on USPTO Three-Track Examination Proposal1 September 2010, 4:52 am
By James DeGiulio -- On June 4, in an effort to address the application backlog and its alleged negative impact on innovation, the U.S. Patent and Trademark Office issued a notice concerning an Enhanced Examination Timing Control Initiative (75 Fed. Reg. 31763). The initiative would, among other provisions, create three examination tracks: an accelerated examination track, a traditional examination track, and a delayed examination track (see "USPTO Director Announces New Examination Options"). A... - USPTO Announces Change to Interview Procedures1 September 2010, 4:34 am
By Donald Zuhn -- Last month, the U.S. Patent and Trademark Office announced a change in the way registered practitioners can show authorization to participate in an examiner interview. Under the old procedure, practitioners were required to file a power of attorney or authorization to act in a representative capacity in order to participate in an interview. Under the new procedure, practitioners need only file an Applicant Initiated Interview Request Form (PTOL-413A). The instruction sheet for ... - The Financial Times' Take on Gene Patenting31 August 2010, 4:59 am
By Kevin E. Noonan -- The staid Financial Times (London) has an article today on the gene patenting debate, and while there are things to criticize in it, the article (perhaps predictably) takes a carefully measured, dispassionate (and welcome) tone ("Who steals the gene from off the common"; free registration required). The paper's conservative bona fides are established on its website: First published in 1888 as a four-page newspaper, the Financial Times' initial readership was the financial c...
- "Reasonable" $600 MILLION Fine for Misbranding BOTOX: I Guess Allergan's Suit Against FDA Paid Off!2 September 2010, 12:52 pm
... - Pharma Email Spam: Three Degrees of Separation for Merck, Pfizer, and Genentech1 September 2010, 6:35 pm
... - Until All of Us Have This "Blue Button," the Online Health Revolution Has Not Even Begun!1 September 2010, 12:34 pm
... - YouTube Fixes Problem I Pointed Out Months Ago: Update on YAZ Case Study31 August 2010, 2:25 pm
...
- American Heart Association, Avandia & Ghostwriting2 September 2010, 2:14 pm
Did the American Heart Association’s Circulation journal publish a ghostwritten article about Avandia? There has been disagreement about this ever since the US Senate Finance Committee released a report in July about the controversy concerning the GlaxoSmithKline diabetes pill. Glaxo, you may recall, once ran a program aptly named Cassper, or Case Study Publications for [...]... - Another Japanese Drugmaker Buys Into Diet Pills2 September 2010, 1:13 pm
For the second time this summer, a Japanese drugmaker has agreed to pay $50 million upfront for the rights to a forthcoming diet pill. This time, Takeda Pharmaceuticals is giving Orexigen Therapeutics $50 million for exclusive North American marketing rights (but co-promotion in the US) for Contrave and another $1 billion for meeting regulatory and [...]... - Merck Blinks Over Plant Closings In The Netherlands2 September 2010, 12:32 pm
After a summer filled with demonstrations and threats from employees to stage walkouts, Merck has decided to postpon the planned closure of some of its operations in the Netherlands while talks are held with on potential alternatives, including a sale of the R&D site, Reuters reports. The last-minute deal avoids a court hearing scheduled fo [...]... - Should The FDA Have Moved Faster On Meridia?2 September 2010, 12:17 pm
After months of waiting, the final and complete results from a study about the Meridia diet pill are now available in The New England Journal of Medicine and the findings are as bad as what was suggested by the preliminary data released last November. The SCOUT study, which was financed by Abbott Labs, the company [...]...
- Improved Vision From New Eye Procedure15 August 2010, 10:22 pm
© FeatheredTarToday, most people are aware of the benefits of Lasik eye surgery for the treatment of an eyesight condition better known as double vision. However, there is a new procedure called laser blended vision surgery. Lasik eye surgery became a popular treatment procedure because of its success in treating the eye's difficulty in focusing up-close objects. This is done by correcting the vision of one eye for distance while the other, for close vision. What is not covered by Lasik ... - Ouch-less Flu Vaccines, Coming Soon21 July 2010, 1:53 pm
© samantha celeraWith the recent development of flu vaccines in the form of Band-Aid like patches, not only can the vaccine be self-administered painlessly, but it can also be ordered and delivered through the mail. The vaccine patches actually contain microneedles that are just three hundredths of an inch in size and only feel like fine sandpaper. These microneedles also dissolve within 15 minutes of application on the skin so there's no need for special disposal procedures, as there wi... - Vision-Aiding Implantable Device, Approved By The FDA8 July 2010, 6:33 am
© paul (dex)The use of micro-sized implantable telescopes to improve vision in patients with end-stage, age-related macular degeneration has been approved by the FDA. A condition that affects older people, age-related macular degeneration (AMD) damages the center of the retina (or macula), resulting in loss of vision in the center of the visual field. Designed to replace the natural lens, the tiny device approved by the FDA is called an Implantable Miniature Telescope (IMT). It provides a... - Human Collagen Production from Tobacco Plants28 June 2010, 1:56 am
© minnemomResearchers have succeeded in producing a replica of human collagen from tobacco plants, possibly making the production of commercially produced collagen for use in surgical implants and many wound healing devices in regenerative medicine. Currently, commercial collagen is produced from farm animals such as cows and pigs as well as from human cadavers and are thus prone to harbor human pathogens such as viruses or prions and, in the case of human cadavers, may possesses serious ethica...
![[Bloglines]](http://www.biotechblog.com/wp-content/plugins/bookmarkify/bloglines.png)
![[del.icio.us]](http://www.biotechblog.com/wp-content/plugins/bookmarkify/delicious.png)
![[Digg]](http://www.biotechblog.com/wp-content/plugins/bookmarkify/digg.png)
![[Facebook]](http://www.biotechblog.com/wp-content/plugins/bookmarkify/facebook.png)
![[Google]](http://www.biotechblog.com/wp-content/plugins/bookmarkify/google.png)
![[LinkedIn]](http://www.biotechblog.com/wp-content/plugins/bookmarkify/linkedin.png)
![[Reddit]](http://www.biotechblog.com/wp-content/plugins/bookmarkify/reddit.png)
![[StumbleUpon]](http://www.biotechblog.com/wp-content/plugins/bookmarkify/stumbleupon.png)
![[Twitter]](http://www.biotechblog.com/wp-content/plugins/bookmarkify/twitter.png)
![[Email]](http://www.biotechblog.com/wp-content/plugins/bookmarkify/email.png)
